Cheng-Zhi Zhou
Overview
Explore the profile of Cheng-Zhi Zhou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weng C, Liu K, Jin S, Su J, Yao Y, Zhou C, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2538-2548.
PMID: 39507030
Background: The B-Raf proto-oncogene, serine/threonine kinase () V600E mutation is responsible for approximately 3% of acquired resistance mechanisms to epidermal growth factor receptor ()-tyrosine kinase inhibitors (TKIs) in advanced -mutant...
2.
Liu G, Zhang X, Xin S, Wang Q, Yan Q, Zhou C, et al.
Huan Jing Ke Xue
. 2023 Sep;
44(9):5222-5230.
PMID: 37699840
CuFeO-modified biochars were prepared through co-precipitation and hydrothermal methods, and the composites had high efficiency removal for tetracycline (TC) from water. The CuFeO-modified biochar with a 2:1 mass ratio of...
3.
Xie X, Shen P, Wu J, Qiu G, Lin X, Xie Z, et al.
Hum Vaccin Immunother
. 2023 Aug;
19(2):2240689.
PMID: 37529904
Immune-related adverse events (irAEs) pose a significant challenge for the widespread adoption of immuno-oncology therapies, but their symptoms can vary widely. In particular, the relationship between irAEs and pleural effusion...
4.
Guo S, Xue Y, Zhu X, Yang B, Zhou C
J Interv Card Electrophysiol
. 2022 Sep;
66(3):597-609.
PMID: 36098833
Background: Zhigancao decoction (ZD) has a long history in China as a traditional Chinese medicine compound for the treatment of tachyarrhythmias. This study mainly explored the pharmacological mechanism of Zhigancao...
5.
Xie X, Deng H, Lin X, Wu J, Liu M, Xie Z, et al.
Front Oncol
. 2021 Jul;
11:673877.
PMID: 34221992
Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs),...
6.
Xie X, Zhan Z, Qin Y, Jiang J, Yin W, Zheng R, et al.
Front Oncol
. 2021 Apr;
11:655856.
PMID: 33816312
The treatment of anaplastic lymphoma kinase (ALK)-positive locally advanced non-small-cell lung cancer (NSCLC) is challenging because there is no randomized controlled trial has been reported. The value of neoadjuvant and...
7.
Xie X, Wang F, Lin X, Qin Y, Xie Z, Zhang J, et al.
Cancer Manag Res
. 2020 Dec;
12:12709-12714.
PMID: 33328765
Objective: The study aimed to analyze the efficacy and safety of combination regimen of anlotinib and S-1 for Chinese patients with EGFR mutation-negative advanced squamous cell lung cancer (SqCLC) with...
8.
Xie X, Wang L, Qin Y, Lin X, Xie Z, Liu M, et al.
Orphanet J Rare Dis
. 2020 Jul;
15(1):183.
PMID: 32650830
Objective: NUT midline carcinoma (NMC), a rare type of squamous cell carcinoma, is genetically characterised by NUT midline carcinoma family member 1 (NUTM1) gene rearrangement. NMC can arise from the...
9.
Li M, Zhou C, Yang J, Lu S, Zheng D, Hu J, et al.
Cancer Biol Ther
. 2019 Apr;
20(8):1097-1104.
PMID: 30990107
Literatures regarding the prevalence and clinical significance of compound EGFR mutations are limited. Until now, none of retrospective or prospective research has focused on compound mutations except case reports. In...
10.
Xu M, Duan X, Chen Q, Fan H, Hong Z, Deng S, et al.
Biomed Pharmacother
. 2018 Dec;
109:2396-2408.
PMID: 30551499
Objective: Compound sophorae decoction, a Chinese medicinal formulae composed of six Chinese herbs, is effective for the clinical treatment of ulcerative colitis (UC). Some of its effective monomers had been...